An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 377 participants.

Also called NCT02235909

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 377 participants (enrolled count) (from the registry)
Sponsor
Arbor Pharmaceuticals, Inc. (from the registry)
Registry
  • NCT NCT02235909
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Brazil, Bulgaria, Colombia, Hungary, Italy, Mexico, Poland, South Africa, Türkiye, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02235909. Randomized; triple masking; primary purpose treatment. Start 2015-03-30 (actual); primary completion 2019-11-11 (actual). Results posted on 2025-02-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension
Condition
Hypertension
Intervention (Drug)
Azilsartan Medoxomil Low-dose
Intervention (Drug)
Losartan
Intervention (Drug)
Placebo for Azilsartan Medoxomil
Intervention (Drug)
Placebo for Losartan
Intervention (Drug)
Azilsartan Medoxomil Medium-dose (20 mg)
Intervention (Drug)
Azilsartan Medoxomil High-dose (40 mg)
Lead sponsor
Arbor Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02235909
Content hash
4848358c5a7a6ad5d3b285ecc5a43ca912bb4dbde9cb54681422c15405266f39